66種中藥材進入歐洲藥典 未來目標達到300種
As of May this year, 66 Chinese medicinal herbs have been added to the European Pharmacopoeia (EP), an authoritative reference work for quality control of medication in Europe.
截至2016年5月，已有66種中草藥進入歐洲藥典。歐洲藥典是歐洲藥品質量管理的權威指導文獻。This means there are clear quality standards for Chinese herbs exported to Europe, which help the drugs gain wider acceptance in foreign markets, according to Professor Dr. Gerhard Franz, Chairman of the TCM (Traditional Chinese Medicine) Working Party of the European Pharmacopoeia.
歐洲藥典中藥委員會主席葛哈德·法蘭茲教授表示，這意味着中草藥出口至歐洲有了明確的質量標準，有助於中藥在國外市場被更廣泛地接受。He made the remarks at an international conference on TCM's future, which was held in Hangzhou, capital of east China's Zhejiang Province.
他是在中國東部浙江省省會杭州市舉辦的關於“中醫的未來”國際峯會上作出上述評論的。
He said the herbs have undergone strict examination and discussion and been approved by all 37 signatory states.
據法蘭茲介紹，進入歐洲藥典的中藥材都經過了嚴格檢測論證，獲得了歐洲藥典所有37個成員國的同意。The listed Chinese herbs account for over a third of all herbs in the pharmacopoeia. He said their goal is to include at least 300 commonly used Chinese herbs.
目前已進入歐洲藥典的中草藥佔歐洲藥典裏草藥總數的1/3以上。法蘭茲稱，未來的目標是把至少300種常用中草藥納入歐洲藥典。Exports of traditional Chinese drugs have been impeded by misuse and substitutions for similar plants, as well as contamination by heavy metals and microbial insecticides.
由於對類似草藥的誤用和替換，以及重金屬和微生物殺蟲劑的污染，中國傳統藥物的出口受到了阻礙。Xu Runlong, deputy head of Zhejiang's health and family planning commission, said due to lack of quality standards, China's TCM industry lags far behind its counterparts in Japan and the Republic of Korea in foreign markets, adding that modern technology and ideas must be applied in developing TCM.
浙江省衛生和計劃生育委員會副主任徐潤龍表示，由於缺乏質量標準，在國外市場，中國的中醫藥產業遠遠落後於競爭對手日本和韓國。此外，他還補充說道，現代技術和理念一定要應用於傳統中醫藥的發展中，
